Am J Transplant, Volume 21, Suppl 3 Archives - Page 63 of 139 - ATC Abstracts

2021 American Transplant Congress
Infectious Complications After Belatacept Conversion in Kidney Transplant
J. E. Marvin¹, D. Amenyedor¹, M. M. Azar², K. Belfield¹, V. Do¹, R. Formica³, E. Cohen¹
¹Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, ³Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Tacrolimus (tac), a calcineurin inhibitor, is associated with multiple adverse effects when used for immunosuppression following kidney transplant (KT). Belatacept (bela) is a monoclonal…
2021 American Transplant Congress
Outcomes of Kidney Transplant Recipients With Sickle Cell Disease: An Analysis of the 2000-2019 UNOS/OPTN Database
N. Leeaphorn¹, C. Thongprayoon², C. Jadlowiec³, A. Chewcharat⁴, P. Hansrivijit⁵, S. Katari¹, P. Vaitla⁶, L. Cummings¹, M. Cooper⁷, W. Cheungpasitporn²
¹Saint Luke's Health System, Kansas City, MO, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴Mount Auburn Hospital, Cambridge, MA, ⁵University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA, ⁶University of Mississippi Medical Center, Jackson, MS, ⁷Medstar Georgetown Transplant Institute, Washington, DC
*Purpose: Lower patient survival has been observed in sickle cell disease (SCD) patients who go on to receive a kidney transplant. This study aimed to…
2021 American Transplant Congress
Use of Granulocyte Colony Stimulating Factor After Lung Transplantation is Not Associated with Increased Likelihood of Acute Cellular Rejection
S. Fredrick¹, C. Iasella², L. Sacha³, R. Rivosecchi³, M. Morrell³, P. Sanchez³, J. Pilewski³, M. Snyder³, J. McDyer³, C. Moore³
¹University of Rochester Medical Center, Rochester, NY, ²University of Pittsburgh School of Pharmacy, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: The cause of neutropenia in lung transplant recipients is multifactorial, including medications, viral infections, and antecedent disease. Granulocyte colony-stimulating factor (G-CSF) is commonly used…
2021 American Transplant Congress
Effect of Multi-Organ Transplant Allocation on Pediatric Kidney Waitlist Candidates
D. Shepherd, R. M. Engen
Pediatric Nephrology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL
*Purpose: Multi-Organ Transplants (MOTs) have variable allocation policies and often take precedence over other waitlist candidates. Lack of defined MOT guidelines divert kidneys to MOT…
2021 American Transplant Congress
Automated Electronic Donor Referrals Have Increased Transplantation
J. Piano
Transplant Connect, Santa Monica, CA
*Purpose: It is well understood and supported by previous studies that costly inefficiencies exist in the current phone-based process by which hospitals refer potential donors…
2021 American Transplant Congress
Use of a Novel Bead-based Assay to Measure the Impact of Imlifidase on ABO IgG Antibodies
A. Halpin¹, B. Motyka², T. Ellis², J. Pearcey², T. L. Lowary³, A. Runström⁴, L. Winstedt⁴, R. Bockermann⁴, S. Järnum⁴, A. Robertson⁴, L. J. West⁵
¹Department of Pediatrics and Laboratory Medicine and Pathology, University of Alberta and Alberta Precision Laboratories, Edmonton, AB, Canada, ²Department of Pediatrics, University of Alberta, Edmonton, AB, Canada, ³Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ⁴Hansa Biopharma, Lund, Sweden, ⁵Department of Pediatrics and Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
*Purpose: The accurate assessment and measurement of ABO antibodies (ABO-Ab) is a critical component of ABO-incompatible (ABOi) transplantation. ABO-Ab comprise both IgG and IgM, which…
2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³U Illinois, Chicago, IL, ⁴Tampa Gen, Tampa, FL, ⁵U Wisconsin, Madison, OH, ⁶Centura Transplant, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
2021 American Transplant Congress
Safety of Sars-cov-2 Mrna Vaccines in Solid Organ Transplant Recipients
M. Ou, B. Boyarsky, J. Motter, R. Greenberg, A. Teles, J. Ruddy, M. Krach, W. Werbel, R. Avery, A. Massie, D. Segev, J. Garonzik-Wang
Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: The safety of SARS-CoV-2 mRNA vaccines in solid organ transplant recipients (SOTRs) remains unknown. We investigated adverse events in SOTRs who received these mRNA…
2021 American Transplant Congress
Sequential Analysis of Renal Allograft Rejection at Single Cell Resolution
T. Shi¹, C. Castro-Rojas¹, A. Burg¹, K. Roskin¹, J. Rush², B. Haraldsson², A. Shields³, R. Alloway³, E. Woodle³, D. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Novartis Pharmaceuticals AG, Basel, Switzerland, ³University of Cincinnati Medical Center, Cincinnati, OH
*Purpose: Renal allograft anti-rejection therapies (corticosteroids (CCS) and anti-lymphocyte globulin) have been the primary treatment modalities for over six decades, yet little is known about…
2021 American Transplant Congress
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of At-1501
S. Perrin¹, A. Gill², C. Gill², P. Gustafson¹
¹Novus Therapeutics, Irvine, CA, ²ALS Therapy Development Institute, Cambridge, MA
*Purpose: Execute a phase 1 study of AT-1501 to assess safety, pharmacokinetics, and functional activity.*Methods: The study employed a placebo-controlled, sequential, dose-escalation design. 28 healthy…